Group 1 - The core point of the article is that Haohai Biological Technology (06826.HK) has entered into a share purchase agreement to acquire approximately 19.8% of Jiangxi Ruiji Biological Engineering Technology Co., Ltd. and an additional 2.4554% by a personal buyer, with the total cash consideration amounting to RMB 38,351,487.36 for the first buyer and RMB 4,755,979.05 for the second buyer [1] Group 2 - The share transfer will be completed in three phases between 2025 and 2026 [1] - The target company's products are primarily used in orthopedics and ophthalmology, addressing tendon injury repair, ocular surface burns, wound and lesion repair, and tear duct obstruction support [1] - By investing in the target company and obtaining distribution rights for its products in China, the group aims to enter the high-value medical device market of biological amniotic membranes, enhancing its existing product portfolio and expanding its business in orthopedics and ophthalmology [1] - The amniotic materials held by the target company possess human-derived biological characteristics, providing the group with critical technology and material foundations in the fields of regenerative medicine and tissue engineering, which is expected to drive future product innovation and technological upgrades [1]
昊海生物科技(06826.HK)分三阶段收购江西瑞济生物19.8%股权 总对价约3835万元